AU1813701A - Interleukin-1 muteins useful as vaccine adjuvants - Google Patents

Interleukin-1 muteins useful as vaccine adjuvants

Info

Publication number
AU1813701A
AU1813701A AU18137/01A AU1813701A AU1813701A AU 1813701 A AU1813701 A AU 1813701A AU 18137/01 A AU18137/01 A AU 18137/01A AU 1813701 A AU1813701 A AU 1813701A AU 1813701 A AU1813701 A AU 1813701A
Authority
AU
Australia
Prior art keywords
mutein
interleukin
muteins
useful
vaccine adjuvants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18137/01A
Other languages
English (en)
Inventor
Richard S. Dondero
Herman F. Staats
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Duke University
Original Assignee
Celltech Chiroscience Ltd
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Chiroscience Ltd, Duke University filed Critical Celltech Chiroscience Ltd
Publication of AU1813701A publication Critical patent/AU1813701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU18137/01A 1999-12-03 2000-12-04 Interleukin-1 muteins useful as vaccine adjuvants Abandoned AU1813701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16892899P 1999-12-03 1999-12-03
US60168928 1999-12-03
PCT/US2000/032813 WO2001039803A2 (en) 1999-12-03 2000-12-04 Interleukin-1 muteins useful as vaccine adjuvants

Publications (1)

Publication Number Publication Date
AU1813701A true AU1813701A (en) 2001-06-12

Family

ID=22613541

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18137/01A Abandoned AU1813701A (en) 1999-12-03 2000-12-04 Interleukin-1 muteins useful as vaccine adjuvants

Country Status (7)

Country Link
US (2) US6656462B2 (https=)
EP (1) EP1196193B1 (https=)
JP (1) JP2003515569A (https=)
AT (1) ATE413191T1 (https=)
AU (1) AU1813701A (https=)
DE (1) DE60040740D1 (https=)
WO (1) WO2001039803A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270758B1 (en) * 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
WO2008037504A1 (en) * 2006-09-28 2008-04-03 Cytos Biotechnology Ag Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
NZ566971A (en) 2005-09-28 2011-06-30 Cytos Biotechnology Ag Vaccine containing a virus like particle linked with an interleukin-1 molecule
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
WO2014085767A1 (en) * 2012-11-29 2014-06-05 University Of Rochester Compositions and methods for treating immune conditions, including type1 diabetes
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
TWI601742B (zh) * 2016-03-23 2017-10-11 國立清華大學 使宿主提早產生抗體及延長抗體保護時間的重組雞介白素１β蛋白質及其應用
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
WO2022011005A1 (en) * 2020-07-07 2022-01-13 Orionis Biosciences, Inc. Immunostimulatory adjuvants
EP4469079A1 (en) 2022-01-28 2024-12-04 Pfizer Inc. Coronavirus antigen variants
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342614A (en) 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US5503841A (en) 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
JP2591615B2 (ja) * 1986-03-14 1997-03-19 大塚製薬株式会社 インターロイキン−１β誘導体及び医薬
IT1217314B (it) 1987-02-20 1990-03-22 Sclavo Spa Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
ATE165114T1 (de) 1989-02-27 1998-05-15 New England Medical Center Inc Il-1, dessen biologische aktivität inhibiert ist
JP3485184B2 (ja) 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체

Also Published As

Publication number Publication date
US20010036452A1 (en) 2001-11-01
US6656462B2 (en) 2003-12-02
EP1196193B1 (en) 2008-11-05
DE60040740D1 (de) 2008-12-18
WO2001039803A2 (en) 2001-06-07
US20040253208A1 (en) 2004-12-16
JP2003515569A (ja) 2003-05-07
WO2001039803A3 (en) 2002-02-21
EP1196193A2 (en) 2002-04-17
ATE413191T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
Mahon et al. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells
Heath et al. Cytokines as immunological adjuvants
Mountford et al. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
ATE229978T1 (de) Helicobacter proteine und impstoffe
Rotman et al. IL‐12 eliminates the Th‐2 dependent protective immune response of mice to larval Strongyloides stercoralis
MD1586F2 (ro) Inducere a unui raspuns citotoxic T-limfocitar
FI920132A0 (fi) Stabila vaccinkompositioner innehaollande interleukiner.
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
EP0327640A4 (en) IMMUNOTHERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME.
FR2677654B1 (fr) Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
Heath Cytokines as immunological adjuvants
ATE422362T1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
WO2015138471A1 (en) Heat inactivated poxvirus improves vaccination results
CA2372181A1 (en) Adjuvant combination formulations
ATE515258T1 (de) Mukosales verabreichungssytem
ATE404218T1 (de) Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
Hughes et al. Potentiation of the immune response by cytokines
SE9604296D0 (sv) New pharmaceutical formulation of polypeptides
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
EP0604727A1 (en) Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
WO1999022763A3 (en) Encapsulated immunomodulators useful as vaccine adjuvants
OA09672A (en) Use of il-4 to enhance immune response to infectious antigenic challenges

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase